Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Luseogliflozin effects on intestinal glucose excretion and gut environment in type 2 diabetes
jRCTs051240181Recruiting
- Sponsor
- Taisho Pharmaceutical
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of luseogliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Taisho Pharmaceutical. Primary endpoint: Hourly excretion of glucose into the intestinal lumen after 12 weeks. Started Feb 2025; status: recruiting.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs051240181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051240181.